Publications

/

• Journal Articles - Clinical pharmacokinetics

  • N Mansoor, R Alam, J Schueller, D Ettlinger, P Buchner, M Czejka,T Ahmad: Irinotecan (CamptoR) Pharmacokinetics and Metabolism in Patients with Elevated Serum Bilirubin Levels. Journal of Cancer Research Updates 2016, 67-72
  • A Farkouh, W Scheithauer, P Buchner, A Georgopoulos, J Schueller, B Gruenberger, M Czejka: Clinical pharmacokinetics of capecitabine in combination with the monoclonal antibody bevacizumab. Anticancer Res 2014, 34: 3669-3673
  • V Schreiber, M Kitzmueller, M Poxhofer, S Gintersdorfer, C Neudorfer, M Lichtneckert, C Dittrich, M Czejka: Impact of co-administered drugs on drug-monitoring of capecitabine in patients with advanced colorectal cancer. Anticancer Res 2014, 34: 3371-76
  • M Czejka , E Ulsperger, H Schnait, T Brumnik, J Schierholz, P Buchner, Greil R: Evidence for the conversion of docetaxel into 7-epidocetaxel in patients receiving conventional Taxotere® based chemotherapy. J Anal Oncology 2014, 3: 73-78
  • M Czejka, A Kiss, E Ostermann, J Schueller, M Ahemd, N Mansoor,  T Ahmad: Metabolic Activation and Inactivation of Irinotecan when Combined with the Human Monoclonal Antibody Bevacizumab. J Analytical Oncol  2013, 2: 218-225
  • M Czejka, A Sahmanovic, P Buchner, T Steininger, C Dittrich: Disposition of erlotinib and its  metabolite OSI420 in a patient with high Bilirubin. Case Rep Oncol 2013; 6: 602-608
  • C Dechant, M Baur, R Böck, M Czejka, A Podczeck-Schweighofer, Ch Dittrich, G Christ: Acute Reversible Heart Failure Caused by Coronary Vasoconstriction due to Continuous 5-Fluorouracil Combination Chemotherapy. Case Reports Oncol 5: 296–301, 2012
  • Czejka M, Kiss A, Koessner C, Terkola R, Schueller J: Clinical pharmacokinetics of irinotecan during intra-arterial chemotherapy of advanced colorectal cancer. Anticancer Res. 31, 3573-78, 2011
  • M Czejka, J Schueller, B Gruenberger, A Farkouh, W Scheithauer: Plasma disposition of capecitabine and its metabolites 5’DFCR and 5’DFUR in a standard and dose-intensified monotherapy regimen. Cancer Chemother Pharmacol, 2011 67(3):613-619 
  • M Czejka, B Gruenberger, A Kiss, A Farkouh, J Schueller: Clinical pharmacokinetics and metabolism of CPT-11 in patients with advanced colorectal cancer when combined with biweekly cetuximab (Erbitux®). Anticancer Research, 2010 (30), 2355-60 
  • Farkouh A, Schueller J, Scheithauer W, Czejka M: Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) during two different capecitabine / oxaliplatin dosage regimens. Int J of Clinical Pharmacology and Therapeutics 2010, 48 (7), 487-488 
  • Czejka M, Greil R, Ulsperger E, Schnait H, Kienesberger K, Brumnik T, Schierholz J, Farkouh A: Evidence for the conversion of docetaxel into 7’-epidocetaxel in patients receiving conventional chemotherapy with taxotere®. Int J of Clinical Pharmacology and Therapeutics. 2010, 48 (7), 483-484
  • K Hochegger, K Lhotta, G Mayer, M Czejka, W Hilbe: Local advanced non-small cell lung cancer and end stage renal disease – a therapeutic challenge. J Nephrology Dialysis Transplantation, 2006 Aug 25 
  • Hochegger K, Lhotta K, Mayer G, Czejka M, Hilbe W: Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. J Nephrol Dial Transplant. 2007 Jan; 22(1):289-90 
  • D Ettlinger, M Mitterhauser, W Wadsak, E Ostermann, A Farkouh, J Schueller, M Czejka: In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab. Anticancer Research 2006 (26) 1337 – 41 
  • MJ Czejka, J Schueller, K Hauer, E Ostermann: Pharmacokinetics and metabolism of CPT-11 combined with capecitabine in patients with advanced colorectal cancer. Anticancer Res, 2005, (25) 2985 – 2990 
  • M Czejka, E Ostermann, L Muric, D Heinz, J Schueller: Disposition of gemcitabine combined with trastuzumab in patients with advanced breast cancer (ABC). Onkologie (Karger), 2005 (28), 318 – 322 
  • A Furtlehner, J Schueller, I Jarisch, E Ostermann, M Czejka : Disposition of paclitaxel (Taxol®) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Herceptin®). Eur J Drug Metab Pharmacokin, 2005. Vol. 30 (3), 145 -150 
  • M Czejka, J Schueller, H Schnait, B Springer I Eder: Clinical pharmacokinetics and metabolism of paclitaxel after 3-hour infusion: comparison of two preparations. J Oncol Pharm Pract, 9, 127-136, 2003 
  • W Linkesch, M Weger, I Eder, HW Auner, C Pernegg, C Kraule and MJ Czejka: Long term pharmacokinetics of doxorubicin stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP) Eur J Drug Metabol Pharmacokin, 26 (3), 179-184 (2001) 
  • MJ Czejka, J Schueller, I Eder, G Reznicek, R Freitag: Clinical pharmacokinetics and metabolism of Paclitaxel after polychemotherapy with the cytoprotective agent amifostine. Anticancer Res 20, 3871 (2000) 
  • M Czejka, J Schueller, I Eder, U Zeleny, C Pernegg: Serum and tissue concentrations of encapsulated doxorubicin (stealth liposomes, Caelyx). Eur J Pharm Sci 11 (Suppl 1), 22 (2000) 
  • I Eder, M Czejka, J Schueller, U Zeleny: Clinical pharmacokinetics and metabolism of irinotecan during mono- and polychemotherapy with 5-fluorouracil/leucovorin and docetaxel. Eur J Pharm Sci 11 (Suppl 1) 23 (2000) 
  • I Eder, M Czejka, M Braunsdorfer, S Strauch, C Dittrich: Pegylated liposomal doxorubicin (Caelyx R), administered intravenously at conventional dosages, penetrates into the brain. Clin Cancer Res 5 (S), 448 (1999) 
  • H Rosen, G Jatzko, S Repse, S Potrc, H Neudorfer, P Sandbichler, J Zacherl, H Rabl, P Holzberger, P Lisborg, M Czejka: Adjuvant intraperitoneal chemotherapy with carbon adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the austrian working group for surgical oncology. J Clin Oncol 16 (8), 2733-38 (1998) 
  • J Schüller, M Czejka, E Krexner, C Pietrzak, B Springer, H Kletzl, D Borow: Amifostine differently influences pharmacokinetics of selected cytostatic agents. Eur J Cancer 33 (1008), 245 (1997) 
  • K Dempe, C Pietrzak, J Schüller, MJ Czejka: Bestimmung von Amifostine im Serum mittels eines einfachen Phosphat Tests: Anwendung für drug-monitoring in der Chemotherapie. Sci Pharm 64, 319-326 (1996) 
  • MJ Czejka, S Bandak, J Schüller, D Simon, C Weiss, E Schermhammer: Pharmacokinetic interaction between 4’-epidoxorubicin and the multidrug resistance reverting agent quinine. Zeitschr Naturforsch (Biosciences) 50c, 565-570 (1995) 
  • MJ Czejka, J Schüller, E Schernhammer, S Bandak: Arzneistoff Interaktion zwischen Interferon--2b und 5-Fluorouracil während fünftägiger iv 5FU Infusion. Die Pharmazie 50 (6), 416-419 (1995) 
  • S Bandak, MJ Czejka, J Schüller, E Schermhammer: Pharmacokinetic drug interaction between epirubicin and interferon--2b in serum and red blood cells. Drug Res 45 (I), 212-215(1995)
  • MJ Czejka, J Schüller, C Pietrzak, S Bandak, S Strauch: Biotransformation von 5-Formyl- zu5-Methyl-tetrahydrofolsäure in Serum und Erythrozyten nach iv Gabe von hochdosiertem (6S)- oder (6R,S)-Calcium Folinat. Sci Pharm 63 (4), 270 (1995)
  • J Schüller, MJ Czejka: Pharmacokinetic interaction of 5-fluorouracil and interferon--2b with or without folinic acid. Medical Oncol Vol 12 (1), 47-53 (1995)
  • J Schüller, M Czejka, S Bandak, D Borow, C Pietrzak, I Marei, G Schernthaner: Comparison of pharmacoki-netics of free and liposome encapsulated doxorubicin in advanced cancer patients. Eur J Cancer 31 (975), 199 (1995)
  • MJ Czejka, J Schüller, C Weiss, S Bandak, B Meyer, D Simon: Disposition of 5-formyl- and 5-methyltetrahydrofolic acid after iv bolus of calcium folinat: pharmacokinetic drug interactionwith preadministered interferon--2b. Eur J Drug Metabol Pharmacokin 20 (4), 255-262 (1995)
  • MJ Czejka, J Schüller, S Bandak, C Weiss, E Schernhammer: Blut- und Gewebskonzentrationen von (6S)- und (6R)-N-5-Methyltetrahydrofolsäure nach iv Gabe von (6R,S)-MTHF. Sci Pharm 62 (2), 143 (1994)
  • J Schüller, MJ Czejka, S Bandak, E Schermhammer, G Schernthaner: Serum and tissue level of     d- and l-methyltetrahydrofolic acid after bolus of (d,l)-MTHF. Proceedings AACR 35, 429 (1994)
  • S Bandak, MJ Czejka, J Schüller: In-vitro and in-vivo binding of epirubicin to red blood cells and human plasma proteins. Zeitschr Naturforsch (Biosciences) 49c. 483-488 (1994)
  • W Scheithauer, T Schenk, MJ Czejka: Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Brit J Cancer 67, 8-9 (1993)
  • MJ Czejka, W Jäger, J Schüller, U Fogl: Clinical pharmacokinetics of 5-fluorouracil under the influence of different doses of interferon. Eur J Drug Metabol Pharmacokin 15 (18), 247 (1993)
  • MJ Czejka, W Jäger, J Schüller, U Fogl, G Schernthaner: Pharmacokinetics of 5-fluorouracil: influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Drug Res 43 (3), 387 (1993)
  • MJ Czejka: Drug interaction between fluorouracil and interferon--2b. Drug Interaction Rep 12 (10), 82 (1993)
  • MJ Czejka, J Schüller, W Jäger, U Fogl, C Weiss, H Kienzel, A Georgopoulos: Influence of biodegradable microspheres on the local bioavailability of mitomycin after ia administration. Int J Exptl Clin Chemother 5 (1), 29 (1992)
  • MJ Czejka, J Schüller, U Fogl: Pharmakokinetik von 5-Fluorouracil nach iv Gabe unter Berücksichtigung der Erythrozyten. Arch Pharm (Weinheim) 325, 73 (1992)
  • MJ Czejka, J Schüller, U Fogl: Influence of (6S)-N-5-formyltetrahydrofolic acid on the bioavailability of 5-fluorouracil combined with interferon--2b. Arch Pharm (Weinheim) 325, 373 (1992)
  • V Huber-Spitzy, MJ Czejka, L Georgiew, E Arocker-Mettinger, G Grabner: Penetration of norfloxacin into the aqueous humor of the human eye. Invest Ophthalm Visual Sciences 33, 1723 (1992)
  • J Schüller, MJ Czejka, G Schernthaner, M Wirth, C Bosse, W Jäger, M Micksche: Pharmacokinetic aspects of interferon--2b after ia or ip administration. Sem Oncology 19 (2), 98 (1992)
  • J Schüller, MJ Czejka, G Schernthaner, U Fogl, W Jäger, M Micksche: Influence of interferon--2b on pharmacokinetics of fluorouracil. Sem Oncology 19 (2), 93 (1992)
  • MJ Czejka, W Jäger, J Schüller: Pharmacokinetics of mitomycin C after bolus injection and chemoembo-lisation of the hepatic artery with spherex starch particles. Eur J Drug MetabolPharmacokin 17 (2), 85 (1992)
  • J Schüller, MJ Czejka, W Jäger, U Fogl, C Weiss, G Schernthaner: Pharmacokinetics of     fluorouracil influenced by escalating dosages of interferon and leucovorin. Annals Oncolgy 3 (Suppl. 5), 55 (1992)
  • J Schüller, MJ Czejka, U Fogl, C Weiss, G Schernthaner: In-vitro interaction and pharmacokinetics of intrahepatic 5-fluorouracil and interferon combined with starch particles. Ann Oncol 3 (Suppl. 5), 56 (1992)
  • MJ Czejka, T Schenk, W Scheithauer: Red-blood-cell partitioning of N-5-methyltetrahydro folic acid after iv administration. Arch Pharm (Weinheim) 325, 741 (1992)
  • T Schenk, MJ Czejka, G Kornek, W Scheithauer: Pharmakokinetische Untersuchung von Epirubicin in Kombination mit der zytostatikaresistenz modulierenden Substanz R-Verapamil. Acta Med Austriaca 19, 76 (1992)
  • MJ Czejka, J Schüller, C Weiss, B Meyer: Disposition of epirubicin and ist aglycon in serum and red blood cells after high dose iv bolus. Int J Exptl Clin Chemother 5, 193 (1992) 
  • J Schüller, MJ Czejka, M Micksche, C Bosse, A Kroiss, G Schernthaner: Biomodulation inregional treatment - pharmacokinetic aspects of intrahepatic 5-fluorouracil in combination with interferon. Reg Cancer Treat 3-4, 167-170 (1992) 
  • MJ Czejka, W Jäger, J Schüller, G Schernthaner: Vergleichende Bioverfügbarkeit von 5-Fluorouracil nach ia, iv und po Verabreichung. Die Pharmazie 46 (8), 587 (1991) 
  • J Schüller, MJ Czejka, C Armbruster, S Kriwanek, A Tuchmann: Pharmakokinetische Aspekte der Bio-mdoulation von 5-Fluorouracil durch Interferon--2b in der Behandlung des fortgeschrittenen     kolorektalen Karzinoms. Acta Chir Austriaca 23 (5/6), 214 (1991) 
  • MJ Czejka, J Schüller, W Jäger, U Fogl, C Weiss, A Georgopoulos: Improvement of the regional bioavailability of 5-fluorouracil: I - Application of biodegradable microspheres and clinical pharmacokinetics. Int J Exp Clin Chemother 4 (3), 161 (1991) 
  • MJ Czejka, J Schüller, W Jäger, U Fogl, C Weiss, A Georgopoulos: Improvement of the     regional bioavailability of 5-fluorouracil: II - Application of hyaluronidase and clinical pharmacokinetics. Int J Exp Clin Chemother 4 (4), 213 (1991) 
  • MJ Czejka, W Jäger, J Schüller: Einfluß des Vasokonstriktors Glycylpressin auf die Biover-    fügbarkeit von Mitomycin . Arch Pharm (Weinheim) 323, 25 (1991) 
  • MJ Czejka, W Jäger, J Schüller, G Schernthaner: Pharmakokinetik und lokale Verfügbarkeit von Mitomycin C: Einfluß von Vasokonstriktion und Chemoembolisation. Drug Res 41 (1),260 (1991) 
  • MJ Czejka, W Jäger, J Schüller, A Teherani: Pharmakokinetik von Carboplatin nach intraperitonealer Verabreichung. Arch Pharm (Weinheim) 324, 183 (1991) 
  • MJ Czejka, W Jäger, J Schüller, U Fogl, G Schernthaner: Pharmakokinetische Aspekte der Kombination von Interferon--2b und Folinsäure mit Fluorouracil. Drug Res 41 (1), 860 (1991) 
  • MJ Czejka, J Schüller, U Fogl, C Weiss: Influence of interferon--2b on the blood plasma levels of ia 5-fluorouracil. Die Pharmazie 46 (11), 817 (1991) 
  • J Schüller, MJ Czejka, M Micksche, U Fogl, M Wirth, G Schernthaner: Pharmacokinetics of 5-fluorouracil biomodulated by interferon with or without leucovorin. Ann Hematol 63, 59 (1991) 
  • J Schüller, MJ Czejka, W Jäger, M Micksche, U Fogl, G Schernthaner: Influence of interferon and leucovorin on the pharmacokinetics of fluorouracil. Eur J Cancer, Suppl 2, 582 (1991) 
  • J Schüller, MJ Czejka, M Micksche, U Fogl, C Armbruster, K Dinstl: Pharmacokinetic aspects of     the modulation of 5-fluorouracil by interferon--2b in advanced colorectal cancer. Acta Chir     Austriaca 23 (1), 36 (1991) 
  • J Schüller, MJ Czejka, W Jäger, A Tuchmann, K Dittrich, K Dinstl: Intrahepatic Mitomycin combined with starch microspheres or vasoconstricting agent for treatment of colorectal liver metastases. Acta Chir Austriaca 23 (1), 37 (1991) 
  • MJ Czejka, J Schüller, W Jäger, U Fogl, A d’Assie, A Georgopoulos: Bioavailability of folinic acid    in serum and red blood cells after iv and ia administration. Int J Exptl Clin Chemother 4 (1), 27 (1991) 
  • J Schüller, C Bosse, A Tuchmann, G Schernthaner, U Fogl, MJ Czejka: Pharmakokinetische Aspekte der Dosiseskalation von rekombinantem Interferon--2b in Patienten nach intraperitonealer und intraarterieller Applikation. Wr Klin Wochenschr 102 (24), 717 (1990) 
  • MJ Czejka, W Jäger, J Schüller: Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients. Die Pharmazie 45 (9), 693 (1990) 
  • MJ Czejka, W Jäger, A Georgopoulos: Pharmacokinetics of mitoxantrone after 2h and 24 h infusion. Eur J Drug Metabol Pharmacokin 15 (3), 219 (1990) 
  • J Schüller, MJ Czejka, M Micksche: Pharmacokinetic aspects of the dose escalation of interferon--2b in patients after ip and ia administration. Annals of Oncology, Suppl Vol i, 34 (1990) 
  • J Schüller, MJ Czejka, W Jäger, K Dittrich, A Kroiss, K Dinstl: Pharmakokinetik von intrahepatal appliziertem Mitomycin C kombiniert mit Spherex oder Glypressin. Acta Med Austriaca 2 (17), 33 (1990)
  •  J Schüller, MJ Czejka, A Tuchmann, C Armbruster: Pharmacokinetics of intrahepatic mitomycin C combined with degradable starch microspheres or vasopressin analogue. Acta Chir Austriaca 22, 47 (1990) 
  • MJ Czejka, A Georgopoulos, H Lackner: Bioavailability of mitoxantrone in patients after 2 h and 24 h infusion. Int J Exptl Clin Chemother 3, 141 (1989) 
  • WA Ritschel, PS Banjernee, HP Koch, MJ Czejka: Cimetidine-sucralfat drug interaction. Meth Find Exptl Clin Chemother 6, 261 (1984) 
  • P Koch, G Pischek, MJ Czejka, W Ritschel: Pharmacokinetic evaluation of norendimide in rats. Meth Find Exptl Clin Chemother 4, 581 (1982)
• Journal Articles - Preclinical and analytical investigations

  • Buchner P, Mihola E, Sahmanovic A, Steininger T, Dittrich Ch, Czejka M: Validation of a simple assay for the quantification of the capecitabine metabolites 5’ – DFCR and 5’ – DFUR for drug monitoring in patients receiving outpatient chemotherapy. Anticancer Research 2013, 30, 881-886
  • M Czejka, G Pakfeifer, L Donhauser, E Mayr, K Kafka, A Farkouh: Long term ingestion of hormonal contraceptive agents – the exogenous factor fort he increased generation of reactive oxygen species? J Pharm Nutr Sci 1, 1-8  2011
  • Farkouh A, Ettlinger, J Schueller, W Scheithauer, M Czejka: A rapid and simple HPLC assay for quantitation of capecitabine for drug monitoring studies. Anticancer Research 30, 5207-5211  (2010)
  • M Czejka: Loop column technique: a new sample cleanup method for the determination of gallopamil from biological matrix. Gallopamil Drugs, MN-WEB-Applikationen, Appl. No: 104690, 1999
  • M Czejka, HP Koch: Extraction of Thalidomide and major metabolites from whole blood. JTBaker.com technical library Application Note, DOC PH-055, 1998
  • I Pernkopf, G Tesch, K Dempe, H Kletzl, J Schüller, MJ Czejka: In-vitro Untersuchungen zur Bindung von Epirubicin an humane Plasmaproteine: Interaktion mit dem Zytoprotektivum Amifostine. Die Pharmazie 51 (11) 897-901 (1996)
  • MJ Czejka, W. Jäger: Loop column technique: a new sample clean-up method for the determination of gallopamil from biological matrix. LC Application (Macherey-Nagel) Appl. No. 469, 124 (1994)
  • MJ Czejka, T Schenk, W Scheithauer: Untersuchungen zur Kombination von 4’-epidoxorubicin mit D-Verapamil und/oder Tamoxifen in Zellkulturen. Die Pharmazie 48, 147 (1993)
  • MJ Czejka, J Schüller: Bindung von 5-Fluorouracil an Serumproteinfraktionen, Erythrozyten und Ghosts unter in-vitro Bedingungen. Arch Pharm (Weinheim) 325, 69 (1992)
  • MJ Czejka, W Scheithauer: In-vitro disposition of folates and 5-fluorouracil in different colon carcinoma cell lines: Sci Pharm 60 (3), 187 (1992)
  • MJ Czejka, J Schüller, M Micksche: Interaction of interferon with microspheres starch particles. Die Pharmazie 47 (5), 387  (1992)
  • MJ Czejka, B Podesser, N Zwölfer: Red blood cell partitioning of gallopamil, verapamil and norverapamil. Il Farmaco 47 (3), 387 (1992)
  • MJ Czejka, J Schüller, W Scheithauer: Red blood cell partitioning of the (6S)- and (6R)-isomer of N-5-formyl-tetrahydrofolic acid. Zeitschrift Naturforsch (Biosciences) 47c, 748 (1992)
  • MJ Czejka, W Jäger, B Podesser, W Zwölfer: Loop column: a new sample clean-up method for the determination of gallopamil from biological matrix. Analytical and bioanalytical Chemistry 342, 200 (1992)
  • MJ Czejka, W Jäger, B Podesser, W Zwölfer: HPLC determination of gallopamil in serum. Recorder 64, 275 (1992)
  • MJ Czejka: Erythrozytenverteilungskoeffizient von Diethylstilboestrol und seinem O-Diglucuronid. Sci Pharm 59, 107 (1991)
  • MJ Czejka: Ciprofibrat: Erythrozytenverteilungskoeffizient und Bindung an Serumproteine. Arch Pharm (Weinheim) 324, 287 (1991)
  • W Jäger, MJ Czejka, C Seelos, J Schüller, U Fogl: Untersuchungen zur Zerfallskinetik von Ftorafur. Sci Pharm 59, 101 (1991)
  • MJ Czejka, J Schüller: Bindung von 5-Fluorouracil an Mikrospheres Stärkepartikel. Arch Pharm (Weinheim) 323, 53 (1991)
  • MJ Czejka, A Georgopoulos, J Schüller, M Georgopoulos: Erythrocytes as apossible carrier for     mitoxantrone. Int J Exptl Clin Chemother 3 (2), 97 (1990)
  • A Georgopoulos, H Koch, MJ Czejka: In-vitro kinetics and metabolism of -phthalimido-glutarimide. Int J Exptl Clin Chemother 3 (4), 135 (1990)
  • W Jäger, MJ Czejka, J Schüller, U Fogl, E Czejka, H Lackner: A rapid and simple HPLC     assay of 5-fluorouracil for bioavailability studies. J Chromatogr Biomed Appl 532, 411 (1990)
  • MJ Czejka, W Jäger, H Lackner, J Schüller: Loop-column: ein neues Extraktionsverfahren zur  HPLC Bestimmung von Adrenalin und Noradrenalin aus biologischer Matrix. Lab Med 14, 387 (1990)
  • A Georgopoulos, MJ Czejka, W Jäger, N Starzengruber, H Lackner: HPLC of teicoplanin: a comparison with a microbiological assay. J Chromatogr Biomed Appl 494, 340 (1989)
  • MJ Czejka, W Jäger, J Schüller: Mitomycin C determination using loop-column extraction: a rapid and very sensitive assay for pharmacokinetic studies with spherex starch particles. J Chromatogr Biomed Appl 497, 336 (1989)
  • A Georgopoulos, S Breyer, MJ Czejka, M Georgopoulos, W Graninger: Activity of teico planin alone and in combination. J Chemother 1 (4), 204 (1989)
  • MJ Czejka, J Schüller: Bindung des Zytostatikums Mitoxantron an Nukleinsäure, Erythrozyten und Plasmaproteine. Sci pharm 57, 168 (1989)
  • MJ Czejka, A Georgopoulos: HPLC-determination of adriblastine in plasma, urine, saliva and liver punctate by column-switching for drug monitoring studies. J Chromatogr Biomed Appl 424, 182 (1988)
  • MJ Czejka, A Georgopoulos: Mitoxantrone determination using HPLC: improved sensitivity  by loop-column injection for pharmacokinetic studies. J Chromatogr Biomed Appl 425, 429 (1988)
  • MJ Czejka, H Koch: Determination of thalidomide and its major metabolites by HPLC.J Chromatogr Biomed Appl 413, 181 (1987)
  • H Koch, MJ Czejka: Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide. Zeitschr Naturforsch (Biosciences) 41c, 1057 (1986)
• Book Chapters and Review Articles

  • P Buchner, A Sahmanovic, V Schreiber, N Baroian, C Dittrich, M Czejka: A simple method for comparing Enzymatic capecitabine activation in various mono- and combination chemotherapies. Pharmacology 95: 29-13 (2015)
  • A Farkouh, M Czejka: Fosfomycin – Renaissance eines „alten“ Arzneistoffs?. ÖAZ, 4 (68) 72-73 (2014)
  • M Czejka, K Schueller: Pharmacokinetic aspects of regional tumour therapy. Boese - Landgraf – Haunstein - Schmoll,   Agileum – Verlag und Gesundheitsakademie (München, Deutschland), p. 3-10, 2012
  • M Czejka, G Pakfeifer, L Donhauser, E Mayr, K Kafka, A Farkouh: Long term ingestion of hormonal contra- ceptive  agents – the exogenous factor for the increased generation of reactive oxygen species (ROS)? J Pharmacy and Nutrit Sciences 2011, 1: 1-8
  • M Czejka, G Pakfeifer, L Donhauser, E Mayr, K Kafka, A Farkouh: Kontinuierliche Einnahme von Präparaten zur hormonellen Verhütung - ein exogener Faktor für die Genese reaktiver Sauerstoffspezies? ÖAZ 2011, 65 (17) 24-27
  • A Farkouh, M Czejka: Die Schattenseiten des Sauerstoffs. ÖAZ 2011, 65 (17) 28-30
  • M Czejka: Kapitel „Pharmakokinetische Aspekte der regionalen Tumortherapie“. In „Kitteltaschenbuch der regionalen Tumortherapie“, Herausgeber: Boese-Landgraf – Haunstein - Schmoll, Agileum – Verlag und Gesundheitsakademie (München, D), S.3 -10 ( 2010)
  • M Czejka, A Farkouh: Theorie und Relevanz der Messung freier radikale und der antioxidativen Kapazität. Der Freie Arzt 12 (1), 54-56 (2010)
  • A Farkouh, M Georgopoulos, M Czejka: Mögliche systemische Nebenwirkungen – Augentropfen ÖAZ 2010,12, 719-722
  • A Farkouh, B Pattart, M Czejka: Oxidative Stress Messung an Linienpiloten. Austrian Cockpit Association INFO 2010, Jul/Aug., S.12-15
  • A Farkouh, I Leitner, W Oberkogler, M Czejka: Möglicher Arzneimittelmissbrauch an der Tara – Denken Sie daran. ÖAZ 2009, 14, 786-791
  • M Czejka: Pharmazeutische Grundlagen in der klinischen Prüfung: Konzepte pharmakokinetischer Unter-suchungen. Onkologie, Suppl 2, Band 31, 29-33 (2008)
  • M Czejka, A Farkouh: Theorie und Relevanz der oxidativen Stressmessung. ÖAZ 20, 976-978 (2006)
  • M Czejka, A Georgopoulos: Pharmakokinetik. AKH Consilium, September 2006
  • R Terkola, MJ Czejka: Chronotherapy – an interdisciplinary task? Eur J Hospital Pharmacy 6, 26-27 (2004) 
  • MJ Czejka, J Schueller, H Kletzl: Zytoprotektion mit Amifostine (Ethyol ) in der Chemotherapie: Meta-Analyse zum pharmakokinetischen Interaktionspotential mit Zytostatika. Sci Pharm, 69, 289-297 (2001)
  • MJ Czejka, J Schueller, H Kletzl, S Strauch, C Pietrzak: Clinical significance of pharmacokinetic drug interactions between interferon-alpha and antineoplastic drugs. ADIS Biodrugs 11 (2), 87-101 (1999)
  • A Georgopoulos, MJ Czejka: Bioavailability and Bioequivalency of Antimicrobial Agents. in: HP Kümmerle, T Murakawa, CH Nightingale (Eds.) „Pharmacokinetics of Antimicrobial Agents: Principles - Methods - Application“ (Ecomed Verlagsgesellschaft, Landsberg/Lech, China-Version, 1997) Chapter III, 142-161
  • A Georgopoulos, MJ Czejka: Biotransformation of Antimicrobial Agents.in: HP Kümmerle, T Murakawa, CH Nightingale (Eds.) „Pharmacokinetics of Antimicrobial Agents: Principles - Methods - Application“ (Ecomed Verlagsgesellschaft, Landsberg/Lech, China-Version, 1997) 265-306
  • J Schüller, MJ Czejka: Einsatz von Chemoprotektoren in der Anthrazyklintherapie – ein Ansatz zu mehr Effektivität und mehr Lebensqualität ? p. 93-101 in: Neue Prinzipien in der Krebsbehandlung (Hrsg.: HJ Staab und P Drings) Georg Thieme Verlag - Stuttgart - New York 1996
  • MJ Czejka, T Schenk, W Scheithauer: Red blood cell partitioning of N-5-methyltetrahydrofolic acid after iv administration. in: SUBIS, Vol. 15 (Erythrocytes), Chapter VI: Membranes, (Sheffield, 1993)
    A Georgopoulos, MJ Czejka: Bioavailability and Bioequivalency of Antimicrobial Agents. in: HP Kümmerle, T Murakawa, CH Nightingale (Eds.) „Pharmacokinetics of Antimicrobial Agents: Principles - Methods -Application“ (Ecomed Verlagsgesellschaft, Landsberg/Lech, 1993) Chapter III, 147-163
  • A Georgopoulos, MJ Czejka: Biotransformation of Antimicrobial Agents.in: HP Kümmerle, T Murakawa, CH Nightingale (Eds.) „Pharmacokinetics of Antimicrobial Agents: Principles - Methods - Application“ (Ecomed Verlagsgesellschaft, Landsberg/Lech, 1993) Chapter VII, 267-304
    A Georgopoulos, MJ Czejka: Bioavailability and Bioequivalency of Antimicrobial Agents.Kapitel II-2.19.3., p 1-16; in: H.P. Kümmerle, Klinische Pharmakologie (Ecomed Verlag, 1991).
  • A Georgopoulos, MJ Czejka: Biotransformation of Antimicrobial Agents.Kapitel II-2.19.7., p 1-38; in: H.P. Kümmerle, Klinische Pharmakologie (Ecomed Verlag, 1991)
  • J Schüller, MJ Czejka: Influence of interferon--2b on pharmacokinetics of 5-fluorouracil. in: Ed. N. Niederl „Advanced Colorectal Cancer - the role of -interferons“ (1991), 6
  • A Georgopoulos, MJ Czejka, W Jäger, HA Dieterich, JJ Fell: HPLC-Analyse von Teicoplanin im Plasma: Ein Vergleich zu einer mikrobiologischen Bestimmungsmethode. FAC Band 10 (2), 165 (1991)
  • A Georgopoulos, MJ Czejka, N Starzengruber: Biotransformation and bioavailability of inhibitors of gyrase. Int J Exptl Clin Chemother 3, 141 (1989)
  • MJ Czejka, H Lackner, A Kohn: Application of an intelligent autosampler in clinical and Pharma
    ceutical research. Int Laboratory 6, 32 (1989)
  • MJ Czejka: Erythrozyten - ein Arzneistoffträgersystem mit Zukunft? Krankenhauspharmazie 7, 268 (1989)
  • W Linkesch, MJ Czejka, A Georgopoulos: Kontinuierliche Mitoxantrontherapie kombiniert mit hochdosiertem Cytosinarabinosid: pharmakokinetische und klinische Ergebnisse. in:Lutz, Heinz,
    Nowotny, Stacher „Leukämien und Lymphome“, Urban & Schwarzenberg (München - Wien - Baltimore, 1988), 76
  • MJ Czejka: Autosampler 460: Erfahrungen in klinischer und pharmazeutischer Forschung. GIT Lab Med 2,8 (1988)
  • MJ Czejka, H Lackner: Interkalation - Einlagerung von körperfremden Substanzen in Nukleinsäuren. Ber ÖGKCh 11, 109 (1988)
  • MJ Czejka: Einsatz des Diodenarray Spektrophotometers HP 8451A in der Biopharmazie. Fachzeitschr Labor 2, 103 (1988)
• Conference Contributions

  • A Sahmanovic Hrgovcic, C Dittrich, M Kitzmüller, A Gruber, N Baroian, P Buchner, M Czejka, A Farkouh: Protonenpumpeninhibitoren - Potential für pharmakokinetische Wechselwirkungen mit peroral verabreichten Arzneistoffen am Beispiel von Erlotinib. 49. Wissenschaftliche Fortbildungswoche der Österreichischen Apothekerkammer, Schladming 6.-10. März 2016
  • M Czejka: Pharmakokinetische Grundlagen und Konzepte in der klinischen Prüfung: ACR-ITR VIEnna dESO Seminar, 27.- 29.11.2015 Vienna, Austria
  • V Schreiber, M Kitzmueller, P Buchner, M LIchtneckert, R Greil, H Geiler, M Czejka Ch Dittrich: Assessment of pharmacokinetic interaction between cetuximab and capecitabine or oxaliplatin in metastatic colorectal cancer patients (AGMT_CAPECET_PK). Eur J Cancer Vol. 50 (3), p. 388, 2015
  • M Czejka: Pharmakokinetische Grundlagen und Konzepte in der klinischen Prüfung: ACR-ITR VIEnna dESO Seminar, 27.- 29.11.2014 Vienna, Austria
  • A Farkouh, A Georgopoulos, M Czejka: Cytostatic drugs and dietary supplements – clinically relevant interactions?  2014 6.-10. Oct , 9th Int Congress on Anticancer Research, Sithonia, Greece
  • M Czejka: Enstehung reaktiver Sauerstoffspezies bei kontinuierlicher Hormoneinnahme. 2014 Oct 10, Freie Radikale Symposium, Frankfurt, Deutschland
  • Ch Dittrich, P Buchner, R Königsberg, M Lichtneckert, G Nirnberger, M Wagner, M Steinhart, M Czejka, K Geissler: Phase 1b trial to evaluate Capecitabine, erlotinib and bevacizumab in patients with unresectable and/or metastatic pancreatic cancer – preliminary results of the REBECA trial including pharmacokinetics and circulating cells.  European Society For Medical Oncology 2014 Sept Madrid, Spain  
  • M. Czejka: Pharmakokinetische Grundlagen und Konzepte in der klinischen Prüfung: CESAR dESO Seminar, 29. - 30.11.2013, Wien
  • Sahmanovic A, Buchner P, Lichtneckert M, Dittrich Ch, Czejka M: Pharmacokinetics of erlotinib  and its main metabolite OSI420 in advanced pancreatic cancer patients when combined with escalating doses of capecitabine. Abstract No. 0347, 15th WCGIC, Barcelona, 3.-6. July 2013
  • M. Czejka: Pharmakokinetische Grundlagen und Konzepte in der klinischen Prüfung: CESAR dESO Seminar, 25. - 27.11.2012, Wien
  • A Sahmanovic, M Czejka, P Buchner, R Terkola, N.N., Ch Dittrich: Clinical pharmacokinetics of erlotinib in advanced pancreatic cancer patients after single and multiple dose. Abstract No. 0155 13th WCGIC, Barcelona, 22. – 25. June 2011
  • M Czejka, P Buchner, A Sahmanovic, R Terkola, Ch Dittrich: Pharmacokinetics and metabolic activation of  capecitabine in advanced pancreatic cancer when given concomitantly with erlotinib and bevacizumab. Abstract No. 0154, 13th WCGIC, Barcelona, 22. – 25. June 2011
  • M Czejka, A Sahmanovic, P Buchner, R Terkola, N.N., Ch Dittrich: Clinical pharmacokinetics of erlotinib in advanced pancreatic cancer patients after single and multiple dose. Abstract No. 0155
    13th WCGIC, Barcelona, 22. – 25. June 2011
  • M Czejka, P Buchner, A Sahmanovic, R Terkola, Ch Dittrich: Pharmacokinetics and metabolic activation of capecitabine in advanced pancreatic cancer when given concomitantly with erlotinib and bevacizumab. Abstract No. 0154, 13th WCGIC, Barcelona, 22. – 25. June 2011
  • M Czejka: Mikropartikel als PK tool für die lokoregionale Chemotherapie München, 11th Sept 2011
    M. Czejka: Pharmakokinetische Grundlagen und Konzepte in der klinischen Prüfung: CESAR dESO Seminar, 25. - 27.11.2011, Wien
  • M. Czejka: Pharmakokinetische Grundlagen und Konzepte in der klinischen Prüfung: ESOd Seminar, 24. - 26.11.2011, Wien
  • M Czejka: Pharmakokinetik von Taxanen. Tagung der Krankenhausapotherker “Neue
    Arzneimittelformulierungen in der Hämatologie und Onkologie“, 17.4.2010, Gumpoldskirchen
  • M. Czejka: Orale versus parenterale Chemotherapie: pharmakokinetische Aspekte. Tagung “orale Chemotherapie – sicher und effektiv”, Wien Altmannsdorf, 9. Oktober 2010
  • M Czejka: Pharmakokinetische Grundlagen und Konzepte in der klinischen Prüfung:
    CESAR dESO Seminar, 25. - 27.11.2010, Wien
  • M Czejka, A Farkouh, C Nedwed, A Georgopoulos, K Kafka, J Schueller: Generation of reactive oxygene species (ROS) during metabolic conversion of epirubicin undergoing chemotherapy. 14th Scientific Meeting of the European Society of Chemotherapy and Infectious Diseases ESCID
    December 8th – 11th, 2010 , Vienna, Austria
  • M Czejka, E Schmutzhard, M Obiditsch, A Georgopoulos, A Farkouh: blood – brain penetration of linezolid in patients with drain associated ventriculitis. 14th Scientific Meeting of the European Society of Chemotherapy and Infectious Diseases ESCID December 8th – 11th, 2010 , Vienna, Austria
  • A Farkouh, D Häusler, M Schnürer, S Reichart, A Gerogiopoulos, M Czejka: Cell uptake of linezolid in granulocytes, lymophocytes and staphyllococcus aureus ATCC 6538. 14th Scientifc Meeting of the European Society of Chemotherapy and Infectious Diseases ESCID December 8th – 11th, 2010, Vienna, Austria   
  • J Schueller, M Czejka, A Kiss, D Ettlinger, E Krexner: Influence of cetuximab on the plasma disposition of CPT-11 and its metabolites in advanced colorectal patients. Ann Oncology, Suppl. 9, Poster Nr. 365P, WCGIC, Barcelona 2009
  • Schueller J, Czejka M, Kiss A, Farkouh A, Aigner K, Krexner E, Gruenberger B: Influence of Cetuximab applied as biweekly infusion on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer. Eur J Cancer Supplements, Vol 7 No 2, September 2009, Page 349
  • Czejka M: Dose adaption at organ dysfunction: the pharmacokinetic academic perspective. CESAR 10th congress. Heiderlberg 29. – 31. October 2009
  • M Czejka: Pharmazeutische Grundlagen der klinischen Prüfung: Konzepte pharmakokinetischer
    Untersuchungen. CESAR ESO-d Seminar, 23. - 25.11.2009, Wien
  • Czejka M, Greil R, Ulsperger E, Schnait H, Kienesberger K, Brumnik T,Schierholz J, Farkouh A: Evidence for the conversion of docetaxel into 7’-epidocetaxel in patients receiving conventional chemotherapy with taxotere®. CESAR 10th congress. Heiderlberg 29. – 31. October 2009   
  • Farkouh A, Schueller J, Scheithauer W, Czejka M: Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) during two different capecitabine / oxaliplatin dosage regimens. CESAR 10th congress. Heiderlberg 29. – 31. October 2009
  • M Czejka: Chemoembolisation von inoperablem HCC: pharmakokinetische Grundkenntnisse
    21.1.2008, Universitätsklinikum Innere Medizin, Graz
  • Schueller J, Czejka M, Farkouh A, Ettlinger D, Krexner E, Gruenberger B: Does dose escalation of
    capecitabine influence its metabolic conversion in metastatic colorectal cancer? 19th Int Congr. Anti Cancer Treatment, Feb. 2008, Paris (Fr)
  • Schueller J, Czejka M, Farkouh A, Aigner K, Krexner E, Gruenberger B: Influence of bevacizumab on pharmacokinetics and metabolism of capecitabine in metastatic colorectal cancer. 19th Int Congr Anti Cancer Treatment, Feb. 2008, Paris (Fr)
  • Czejka M: praktische Relevanz der Messung von Oxidativen Stress und antioxidativer Kapazität.
    DAS Seminar zur Gesundheitsvorsorge, 3. Juni 2008, Wr. Neustadt
  • Czejka M: praktische Relevanz der Messung von Oxidativen Stress und antioxidativer Kapazität.
    DAS Seminar zur Gesundheitsvorsorge, 4. Juni 2008, Graz
  • Schueller J, Czejka M, Krexner E, Aigner K, Gruenberger B: Doxorubicin pharmacokinetics following two different liposomal formulations (Caelyx versus Myocet) in advanced breast cancer patients.
    31st San Antonio Breast Cancer Symposium, Dec 10. – 15. 2008, Texas, USA, No. 550711
  • M Czejka: Pharmazeutische Grundlagen der klinischen Prüfung: Konzepte pharmakokinetischer
    Untersuchungen. CESAR ESO-d Seminar, 23. - 25.11.2008, Wien
  • J Schueller, M Czejka: Vergleichende Anthrazyklin Pharmakokinetik – von Doxorubicin bis Myocet®
    AGO Jahrestagung, Satellitensymposium, 19. April 2007, Salzburg
  • J Schueller, M Czejka: Vergleichende Anthrazyklin Pharmakokinetik – von Doxorubicin bis Myocet®
    Anthrazyklin Therapie einst und jetzt aus pharmazeutischer Sicht, Fortbildungsveranstaltung für Krankenhausapotheker, 4. Mai 2007, Wien
  • Czejka M, Kiss A, Maehr B, Wassertheurer C, Wachouschek M: Möglichkeiten der oxidativern
    Stressmessung als Biomarker und Screeningmodell in der betriebliche Vorsorge. Personal Austria
    Messe (Austria Center, 22. – 23. November 2007)
  • M.Czejka: Methoden der klinischen Prüfung in der Onkologie. CESAR ESO-d Seminar, 23. - 25.11.2007 Wien
  • M Czejka: Workshop über Pharmakokinetik und Metabolismus in der Onkologie. ASAP – ASOP
    Fortbildungsveranstaltung für Krankenhausapotheker. Wien, 13./14. Jänner 2006
  • Schueller J, Czejka M, Kiss A, Krexner E: Influence of bevacizumab on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer patients ASCO 2006
  • Schüller J, Czejka M, Kiss A, Krexner E, Aigner K: Influence of bevacizumab on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer patients.
    ESMO September 2006, Istanbul, Türkei
  • M Czejka, M Wachouschek: Die oxidative Stressmessung als Biomarker in der onkologischen
    Rehabilitation. BVA Sozialversicherung Rehabilitationszentrum, (Bad Tatzmannsdorf, 29.9.2006)
  • M Czejka: Methoden der klinischen Prüfung in der Onkologie. CESAR ESO-d Seminar 23. - 25.11.2006 Wien
  • M Czejka, A Georgopoulos: Pharmakokinetik. E-book; AKH Consilium, Oktober 2006
  • M Czejka, J Schueller, A Farkouh, D Ettlinger, E Ostermann: Clinical pharmacokinetics (PK) and metabolism of CPT-11 (Campto®) when combined with cetuximab (Erbitux®) in patients with advanced colorectal cancer (ACRC). ASCO 2005, Abstract No. 3715
  • M Czejka: Pharmakokinetische Analysen, Interpretationen und Computersimulationen in der pharmazeutischen Onkologie. Fortbildungsveranstaltung SMZ-Süd, Wien (17. Feb. 2005)
  • M Czejka, D Ettlinger, A Farkouh, J Schueller, W Scheithauer: Disposition of irinotecan (CPT-11) and its metabolites SN-38 and APC in HT-29 adenocarcinoma cells: influence of capecitabine on cell-uptake? Proceedings CESAR (Vienna, 7. – 9. Juli 2005) No. 6 / 80
  • M Czejka: Theorie und Relevanz der Klinischen Pharmakokinetik. Vortrag bei Ebewe Pharma,
    Unterach (20. Sept. 2005)
  • R Terkola, M Peinsipp, E Ostermann, J Schueller, M Czejka: Evaluation of an optimized model of chronotherapy with oxaliplatin / 5-fluorouracil / leucovorin. International Conference Cancer and Rhythm: a new challenge in occupational medicine. October 14.-16. 2004, Graz, Poster page 4
  • J Schueller, M Czejka, E Ostermann, L Muric, D Heinz: Influence of Herceptin on pharmacokinetics of taxanes (paclitaxel or docetaxel) or gemcitabine in breast cancer patients. 27th San Antonio Breast Cancer Symposium (8.-11. Dec. 2004, Texas, San Antonio)   
  • M Czejka, J Schueller, D Heinz, A Furtlehner, E Ostermann: Pharmacokinetics and metabolism of gemcitabine, paclitaxel or epirubicin (+ docetaxel) combined with herceptin. 14th Int Congr Anticancer Treatment, 1st – 4 th February 2003 (Paris, FR) Abstract 
  • M Czejka, J Schueller, K Hauer, U Zeleni, E Ostermann, I Eder: Pharmacokinetics and metabolism of irinotecan (Campto®) combined with capecitabine (Xeloda®) in patients with advanced colorectal cancer (ACRC): altered disposition of the metabolites SN-38 and SN-38 glucuronide? ECCO 12, 21.- 25. September 2003 (Copenhagen, DK) Abstr. M574
  • M Czejka: Einsatzmöglichkeiten der Pharmakokinetik in der antineoplastischen Chemotherapie: Drug monitoring und Dosisindividualisierung. Vortrag Landeskrankenhaus Steyr, 28. Okt. 2003
  • K Hauer, J Schueller, D Loschy, P Esletzbichler, E Ostermann, MJ Czejka: Pharmacokinetics (PHK) and metabolism of irinotecan (CPT-11, CAMPTO®) after polychemotherapy with capecitabine (CCB, Xeloda®): in-vivo and in-vitro results. 12th International Congress on Anticancer Treatment 2002, (2. – 6. Feb. Paris)
  • A Furtlehner, M Czejka: An overview of drug metabolism: focus on antineoplastic drugs (ADs).
    ISOPP VIII Int. Congr. Oncol. Pharm. (Vancouver, Canada, 6.-8. Mai 2002)
  • A Furtlehner, M Czejka: Phase II metabolic drug interactions of antineoplastic drugs (ADs)
    ISOPP VIII Int. Congr. Oncol. Pharm. (Vancouver, Canada, 6.-8. Mai 2002)
  • M Czejka: Pharmakokinetische Konzepte in der Onkologie: praktische Anwendungen
    NDO/PODOS (Wien, 6.-8. Sept., 2002)
  • D Heinz, M Czejka: Workshop: Pharmakokinetik und Metabolismus von Zytostatika: Von der
    Versuchsplanung bis zum statistischen Endergebnis. NDO/PODOS (Wien, 6.-8. Sept., 2002)    
  • M Czejka: Möglichkeiten und Grenzen der Pharmakokinetik in der Onkologie. Kongress PODOS
    26.-27. April 2001, Aarau, Schweiz
  • R Terkola, J Schueller, M Czejka: Aufbau eines interdisziplinären Chronotherapieservices mit
    L-OH/5FU/LV. Kongress PODOS 26.-27. April 2001, Aarau, Schweiz
  • J Schueller, M Czejka, I Eder, U Zeleny, A Niedermayr, R Terkola: Influence of herceptin on pharmacokinetics of epirubicin and docetaxel. Proceedings ASCO, Vol. 20, 117a (No. 464), San Francisco (USA) 2001
  • J Schueller, M Czejka, I Eder, E Ostermann, U Zeleni: Serum and tissue kinetics of liposomal encapsulated doxorubicin (Caelyx) in advanced breast cancer patients. 24th San Antonia Breast Cancer Symposium, 10. – 13. Dezember San Antonio, USA 2001
  • M Czejka, J. Schueller, I. Eder,. R. Freitag, U. Zeleni, E. Woltz: Long term pharmacokinetics (PHK) of liposomal doxorubicin (DOXO) given as Caelyx stealth liposomes in repeated cycles of chemotherapy. 10th International Congress on Anticancer Treatment 2000, Paris
  • I Eder, M. Czejka, J. Schueller, U. Zeleny: Pharmacokinetics (PHK) and metabolism of epirubicin (EPI) in combination with docetaxel (TXT). 10th International Congress on Anticancer Treatment 2000, Paris
  • F Kober, M Czejka, H Schmoll, A Heiss, R Kühn, R Roka: Pharmacokinetic data of mitomycin C
    in aorto-cavale hypoxic abdominal chemoperfusion. Österr. Chirurgenkongress , Innsbruck 2000
  • M Czejka, J Schueller, I Eder, B Ehn, U Zeleni, R Freitag: Clinical pharmacokinetics and metabolism of paclitaxel combined with the cytoprotective agent amifostine (Ethyol). Oral presentation. 6th European Congress of Pharmaceutical Sciences, Budapest 2000
  • I Eder, J. Schueller, M. Czejka, U. Zeleny, C. Wetschka: Pharmacokinetics (PHK) and metabolism of epirubicin (EPI) in combination with docetaxel (TXT): in-vitro-in-vivo correlation. Oral presentation. 6th European Congress of Pharmaceutical Sciences, Budapest 2000
  • J Schueller, M Czejka, I Eder, Ch Kraule, E Buchal, U Zeleny: Pharmacokinetics and metabolism of paclitaxel in combination with the cytoprotective agent amifostine. Onkologie 23 (7), 172 (2000)
  • H Auner, M Weger, M Czejka, W Linkesch: Pharmacokinetic and phase I/II study of liposomal doxorubicin (Caelyx) in combination with cyclophosphamide, vinorelbine and prednisone (Hyper-CCVP) for poor prognosis aggressive non-Hodgkin’s lymphoma. Onkologie 23 (7), 150 (2000)
  • Schueller, M Czejka, I Eder, U Zeleny, A Niedermayr: Epirubicin (EPI) docetaxel (DOCE) – pharmacokinetics (PK) of the combination in breast cancer patients. ASCO 2000, New Orleans, USA
  • J Schüller, M Czejka, H Kletzl, M Wirth, B Springer, S Kriwanek, R Terkola, G Schernthaner: Doxo-
    rubicin and Taxotere - a pharmacokinetic study of the combination in advanced breast cancer. Proc
    ASCO 1999
  • I Eder, M Czejka, M Braunsdorfer, S Strauch, Ch Dittrich: Caelyx passes through the blood-brain barrier after intravenous administration of conventional dose. AACR-NCI-EORTC (November 1999, Washington, USA)
  • M Czejka: Influence of cytoprotective agents on the pharmacokinetics and metabolism of different antineoplastic drugs. Fortbildungstagung für Krankenhausapotheker, Vortrag Wilheminenspital - (30. Juni 1999)
  • M Czejka, J Schueller, W Linkesch, I Eder, U Zeleny, C. Pernegg: “Serum and tissue concentrations of encapsulated doxorubicin (stealth liposomes, Caelyx)” 28th Symposium European Society Clinical Pharmacy (Berlin, 1999)
  • I Eder, M Czejka, J Schueller, B Springer, B Scheiber: “Clinical Pharmacokinetics and red blood cell partitioning of topotecan during consecutive chemotherapy.” ECCO 10 (Vienna 1999)
  • I Eder, M Czejka, J Schueller, B Scheiber, U Zeleny: “Irinotecan: Untersuchungen zur Pharmako-kinetik und Metabolismus in der Mono- und Polychemotherapie mit 5-Fluorouracil und Leukovorin”. ÖPhG (Innsbruck 1999)
  • M Czejka, I Eder, J Schueller, U Zeleny: “Bestimmung von Paclitaxel und seinen Metaboliten aus biologischer Matrix: Anwendungen für Drug Monitoring in der Polychemotherapie”. ÖPhG (Innsbruck 1999)
  • I Eder, M Czejka, J Schueller, U Zeleny: “Clinical pharmacokinetics (PHK) and metabolism of irinotecan (IRINO) during mono- and polychemotherapy with 5-Fluorouracil/Leucovorin (5FU/LV) and Docetaxel (DOCE)” 28th Symposium European Society Clinical Pharmacy (Berlin , 1999)
  • C Kraule, M Czejka, J Schueller, E Krexner: “A pharmacokinetic (PK) study of the interaction of the combination of Taxotere (TXT) and Doxorubicin (DOX)” AAPS 1999, New Orleans
  • M Weger, M Czejka, W Linkesch: A phase-I pharmacokinetic study of Doxil (liposomal doxorubicin) in therapy with vinorelbine, cyclophosphamide and prednisone in NHL. Proc. ASCO, Abstract 894, 1999
  • H Kletzl, MJ Czejka, J Schüller, B Springer, C Pietrcak: In-vitro and in-vivo interaction between
    doxorubicin, epirubicin and the cytoprotective agent amifostine. 8th Int Congr Anticancer Chemother,
    abstract No. P332 (Paris, Feb. 1998)
  • J Schüller, M Czejka, E Krexner, C Pietrzak, B Springer, H Kletzl, D Borow. Amifostine differently
    influences the pharmacokinetics of selected cytostatic agents. 1998
  • M Czejka, J Schüller, I Eder, B Springer, M Roselieb: Clinical pharmacokinetics and red blood cell
    partitioning of topotecan during consecutive chemotherapy. Abstract No. 269, NCI-EORTC (June
    1998, Amsterdam)
  • J Schüller, M Czejka, E Krexner, B Springer, I Eder, R Terkola: Influence of paclitaxel (PAC) on
    topotecan (TPT) pharmacokinetics (PK) in advanced cancer patients. Ann Oncology 9 (Suppl 4)
    132 (1998)
  • J Schüller, M Czejka, H Kletzl, M Wirth, B Springer, S Kriwanek, R Terkola, G Schernthaner: Doxorubicin (DOX) and Taxotere (TXT) – a pharmacokinetic (PK) study of the combination in
    advanced breast cancer. Proc ASCO 17, abstract 790, 205a (1998)   
  • J Schüller, MJ Czejka, C Pietrzak, B Springer, M Wirth, G Schernthaner: Influence of the
    cytoprotective agent amifostine on pharmacokinetics of paclitaxel and taxotere. Proc. ASCO , May 1997
  • S Strauch, M Czejka, J Schüller, H Kletzl, S Mecl: HPLC Bestimmung von Docetaxel in Humanserum und Erythrozyten. Forum Analytik (Wien, 21. - 23. Jänner, 1997)
  • H Kletzl, M Czejka, M Dürrschmid, A Hellwig, N Lechner, J Schüller: Bestimmung von Epirubicin Glucuroniden im Humanserum. Forum Analytik (Wien, 21. - 23. Jänner, 1997)
  • M Czejka, H Kletzl, M Hannaberger, J Schüller: Untersuchungen zur Interaktion von ICRF-187 mit
    Doxorubicin. 13. Jahrestagung ÖPhG, Wien (1997)
  • S Strauch, M Czejka, J Schüller, H Kletzl, M Wachter: Untersuchungen zum Einfluß von Doxorubicin auf die Plasmakonzentrationen von Docetaxel. 13. Jahrestagung ÖPhG, Wien (1997)
  • H Kletzl, M Czejka, J Schüller, S Strauch, N Lechner: Serumverfügbarkeit von Doxorubicin und Epirubicin unter dem Zytoprotektivum Amifostine. 13. Jahrestagung ÖPhG, Wien (1997)
  • S Bandak, M Czejka, J Schüller: In-vitro and in-vivo binding of epirubicin to human red blood cells. 5th Int Congr Anticancer Chemother, abstract o264 (Paris, Februar 1995)
  • J Schüller, M Czejka, C Pietrzak, I Marei, C Armbruster, S Kriwanek, K Dinstl: Pharmakologische Aspekte der Biomodulation von 5-Fluorouracil durch Folinsäure. 36. Tagung Österr Gesell Chirurgie (Wien, Juni 1995)
  • J Schüller, M Czejka, C Pietrzak, I Marei, C Armbruster, K Dittrich, K Dinstl: Pharmakologische Aspekte der Biomodulation von 5-Fluorouracil durch Folinsäure. Acta Chir Austriaca Suppl 114, 104 (1995)   
  • J Schüller, MJ Czejka, S Bandak, E Schermhammer, G Schernthaner: serum and tissue levels of l-leucovorin or methyltetrahydrofolic acid after iv bolus injection: an alternative way of5-fluoro- uracil biomodulation ? Jahrestag Österr Gesell Hämatologie Onkologie (Okt 1994, Wien)
  • J Schüller, MJ Czejka, S Bandak, M Wirth, D Borow, E Schernhammer, G Schernthaner: Influence of interferon--2b on pharmacokinetics of 5-fluorouracil applied as continuous infusion. Jahrestag Österr Gesell Hämatologie Onkologie (Okt 1994, Wien)
  • J Schüller, MJ Czejka, S Bandak, E Schermhammer, G Schernthaner: Serum and tissue levels of d- and l-methyltetrahydrofolic acid. Frühjahrstag Österr Gesell Hämatologie Onkologie (März 1994, Wien)
  • J Schüller, MJ Czejka, S Bandak, C Weiss, E Schermhammer: Pharmacokinetics of (6RS)- or (6S)-leucovorin in serum and red blood cells. Annals Hematology Suppl. 67, Nr. 446 (1993)
  • J Schüller, MJ Czejka, S Bandak, G Schernthaner: Epirubicin pharmacokinetics in serum and red blood cells influenced by quinine. Annals Hematology Suppl. 67, Nr. 445 (1993)
  • J Schüller, MJ Czejka, S Bandak, E Schermhammer, G Schernthaner: Serum and tissue levels of d- and l-methyltetrahydrofolic acid after bolus of (d,l)-MTHF. Proc AACR 35, Nr. 2561 (1994)
  • J Schüller, MJ Czejka, S Bandak, M Wirth, E Schermhammer, G Schernthaner: Epirubicin pharmaco-kinetics - influence of interferon--2b in advanced cancer patients. Proc ASCO 13, Nr. 446 (1994)
  • J Schüller, MJ Czejka, C Weiss, U Fogl, A Kroiss, M Micksche: Biomodulation in regional reatment - pharmacokinetics helpful for treatment planning ? 4th Int Congr Anticancer Chemother, bstract 192, 98 (Paris, 1993)
  • J Schüller, MJ Czejka, C Weiss, M Wirth, M Micksche, G Schernthaner: In-vitro interaction and pharmacokinetics of intrahepatic interferon combined with starch microspheres. 4th Int Congr Anticancer Chemother, Abstract 183, 183 (Paris, 1993)
  • Schüller, MJ Czejka, S Bandak, C Weiss, M Wirth, G Schernthaner: Epirubicin pharmacokinetics in serum and red blood cells influenced by quinidine. Frühjarstagung der Osterr Gesell ämatologie Onkologie (Wien, 1993)    
  • Schüller, MJ Czejka, S Bandak, C Weiss, G Schernthaner: Red blood cells - a considerable
    subcompartment for racemic and L-leucovorin. Proc of AACR, Vol. 34, Nr. 1194 (1993)
  • Schüller, MJ Czejka, S Bandak, M Micksche: Epirubicin pharmacokinetics in serum and red
    blood cells and influenced by quinidine. Proc of AACR, Vol. 34, Nr. 1270 (1993)
  • Kornek, M Czejka, W Scheithauer: Pharmacokinetic interaction between epirubicin and themultidrug reverting agent D-verapamil. Proc of AACR, Vol. 34, Nr. 1269 (1993)
  • J Schüller, MJ Czejka, C Weiss, G Schernthaner: Pharmacokinetic interactions between interferon--2b, folinic acid and fluorouracil. Proc of ASCO 12, Nr. 387 (1993)
  • Schüller, MJ Czejka, S Bandak, C Weiss, G Schernthaner: 5FU - leucovorin biomodulation:
    pharmacokinetic interactions of different schedules used for GI cancer treatment. XI CILAG
    Congr (Cancun, 1993)
  • Schüller, MJ Czejka, S Bandak, C Weiss, M Micksche, G Schernthaner: Epirubicin harmacokinetics in serum and red blood cells and influenced by quinidine. XI CILAG ongr (Cancun, 1993)
  • Schüller, MJ Czejka, S Bandak, C Weiss, M Micksche: Pharmacokinetics of 5FU influenced y escalated dosages of IFN--2b and double modulation IFN with leucovorin. XI CILAG ongr (Cancun, 1993)
  • Buchbauer, L Jirovetz, MJ Czejka, C Näsl, H Dietrich: New results in aromatherapy research. 24th Int Symp Essential Oils (Berlin, Juli 1993)
  • Czejka: Methoden der Probenvorbereitung aus biologischem Material. Fortbildungsveranstaltung Fa. Anyltical Medical Instruments (Wien, Nov 1993)
  • MJ Czejka: Pharmakokinetische Aspekte der Biomodulation von 4’Epidoxorubicin. Fortbildungstagung der Österr Krankenhauspharmazie (Wien, Nov 1993)
    
  • T Schenk, M Czejka, G Kornek, W Scheithauer: Pharmakokinetische Untersuchung von Epirubicin in Kombination mit der zytostatisch Resistenz modulierenden Substanz R-Verapamil. 23. Jahrestagung Innere Medizin (Wien, 1992)
  • J Schüller, MJ Czejka, B Meyer, M Wirth, C Weiss, M Micksche: In vitro interaction and pharmaco-kinetics of intrahepatic 5-fluorouracil combined with starch microspheres. Proc Am Soc Oncol 1992
  • M Czejka, HP Koch: HPLC Monographie “Thalidomid” in: HPLC Methods on Drug Analysis (ed.: M. K. Gosh) Springer Verlag (Berlin, Heidelberg, New York , 1992) p.505-506
  • J Schüller, MJ Czejka, C Bosse, M Wirth, G Schernthaner: Pharmacokinetics of intrahepatic
    5-fluorouracil preinjected with hyaluronidase. Proc Am Ass Cancer Res 32, 173 (1991)
  • A Georgopoulos, F Chmelisek, A Hammerle, S Breyer, MJ Czejka: Pharmacokinetics of    aztreonam during hemofiltration. 17th Int Congr Chemother (Berlin, 1991)
  • J Schüller, MJ Czejka, M Micksche, U Fogl, A Wirth, G Schernthaner: Pharmacokinetics of
    5-fluorouracil biomodulated with IFN--2b with or without leucovorin. VI Eur Interferon Workshop (Hannover, 1991)
  • J Schüller, MJ Czejka, U Fogl, G Schernthaner: Influence of IFN--2b and leucovorin on the
    pharmacokinetics of 5-fluorouracil. Proc ASCO 10, 98 (1991)
  • J Schüller, MJ Czejka, W Jäger, U Fogl, M Wirth, A Kroiss: Pharmacokinetics of intrahepatic
    chemotherapy combined with degradable microspheres or vasopressin analogue. Int Congr Reg
    Chemother, Nr 18 (Osaka, 1991)
  • J Schüller, MJ Czejka, Mmicksche, C Bosse, A Tuchmann, G Schernthaner: Biomodulation in
    regional treatment - pharmacokinetics of intrahepatic 5-fluorouracil combined with interferon
    and leucovorin. Int Congr Reg Chemother, Nr 10 (Osaka, 1991)
  • J Schüller, MJ Czejka, W Jäger, C Weiss, A Kroiss: Pharmacokinetics of intrahepatic chemotherapy combined with degradable microspheres or vasopressin analogue. Workshop on bioreductive drugs, sensitizers, oxygen and radiotherapy (Wien, 1991)
  • J Schüller, MJ Czejka, W Jäger, M Micksche, U Fogl, G Schernthaner: The role of biomodulation in regional treatment - pharmacokinetics of intrahepatic 5-fluorouracil combined with interferon and leucovorin. 7th NCI EORTC Symposium on new drugs in cancer therapy Abstract 541 (Amsterdam, 1991)
  • J Schüller, MJ Czejka, A Tuchmann, C Armbruster, K Dinstl: Pharmacokinetics of intrahepatic Mitomycin C combined with degradable starch microspheres or vasopressin analogue.     31. Tag Österr Gesell Chirurgie (Wien, 1990)
  • J Schüller, MJ Czejka, W Jäger, K Dittrich, A Kroiss, K Dinstl: Pharmakokinetik von intrahepatisch aplliziertem Mitomycin C kombiniert mit Stärkemikrosphären oder Vasopressin Analog (Glypressin). 21 Tag Österr Gesell Innere Med (Wien, 1990)
  • J Schüller, MJ Czejka, C Bosse, A Tuchmann, G Schernthaner: Intrahepatic mitomycin combined with biodegradable starch microspheres or vasopressin analogue: a comparative pharmacokinetic study. Proc 26th Am Soc Oncol Vol 9, Abstr 430 (1990)
  • J Schüller, MJ Czejka, M Micksche, W Jäger, U Fogl: Pharmacokinetic aspects of IFN--2b after ip- and ia-administration. 5th Congr Eur Soc Surg Oncol (Brüssel, 1990)
  • J Schüller, MJ Czejka, W Jäger, A Tuchmann, A Kroiss, K Dinstl: Intrahepatic MMC combined with mircospheres or vasoconstricring agent. 5th Congr Eur Soc Surg Oncol (Brüssel, 1990)
  • J Schüller, MJ Czejka, M Micksche, W Jäger: Pharmacokinetics aspects of the dose escalation of IFN--2b in patients after ip and ia administration. ESMO Congr (Kopenhagen, 1990)       
  • J Schüller, MJ Czejka, A Kroiss, M Wirth, U Fogl: Intrahepatic mitomycin C coinjected with bio- degradable starch microspheres in hepatic intraarterial chemotherapy. IV Int Congr Adv Chemother (Berchtesgarden 1989)
  • J Schüller, MJ Czejka, A Kroiss, M Wirth, U Fogl: Intrahepatic Mitomycin C coinjected with microspheres or vasoconstricting agent - a phase II pharmacokinetic study. Jahrestag Österr Gesell Hämatologie Onkologie (Wr. Neustadt, 1989)
  • J Schüller, MJ Czejka, C Bosse, A Kroiss, M Wirth, U Fogl: Intrahepatic Mitomycin C coinjected     with microspheres or vasoconstricting agent - a phase II pharmacokinetic study. EORTC Symposium Adv Gastrointest Cancer Res Treatment (Strasbourg, 1989)  
  • W Linkesch, MJ Czejka, A Georgopoulos: Continuous infusion of mitoxantrone combined with high-dose cytosinarabinoside: pharmacokinetic study and first clinical results. XXII Congr Int Soc Hematology, Abstr OPM 57, 114 (1988)
  • J Schüller, MJ Czejka, A Tuchmann, M Wirth, A Georgopoulos: Intraarterial mitoxantrone:
    clinical and pharmacokinetics evaluation. Progr Reg Cancer Chemother I, Topic 6, 84 (Vienna, 1988)
  • A Georgopoulos, S Breyer, MJ Czejka, M Georgopoulos: Activity of teicoplanin alone and in
    combination. 6th Med Congr Chemother (Taormina, 1988)
  • MJ Czejka: Einsatz der Diodenarray Spektroskopie in der Biopharmazie. Forum Analytik (Wien, 1987)
  • MJ Czejka, A Georgopoulos: Bestimmung von Adriblastin und Adriblastinol in Serum und Urin für drug-monitoring in der Chemotherapie. Forum Analytik (Wien, 1987)
  • MJ Czejka: Katecholaminbestimmung in Plasma und Urin. Symposium „HPLC in der klinischen Chemie“ (Linz, 1986)
  • MJ Czejka: Interkalation von Zytostatika in Desoxyribonukleinsäuren. Forum Analytik (Wien, 1985)